Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

ALNYLAM PHARMACEUTICALS, INC.

(ALNY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Alnylam Pharmaceuticals : to Webcast Presentation at 43rd Nasdaq Virtual Investor Conference

11/26/2020 | 09:09am EST

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 43rd Nasdaq Virtual Investor Conference on Friday, December 4, 2020 at 11:00 am ET.

A live audio webcast of the presentation will be available on the Investors section of the Company's website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its 'Alnylam 2020' strategy of building a multi-product, commercial-stage biopharmaceutical company with a sustainable pipeline of RNAi-based medicines to address the needs of patients who have limited or inadequate treatment options. Alnylam is headquartered in Cambridge, MA.

Contact:

Tel: 617-682-4340

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about ALNYLAM PHARMACEUTICALS, INC.
01/25ALNYLAM PHARMACEUTICALS : BMO Capital Downgrades Alnylam Pharmaceuticals to Mark..
MT
01/22PRESS RELEASE : BB BIOTECH AG: Vaccines leading -2-
DJ
01/13ALNYLAM PHARMACEUTICALS : Cowen Adjusts Price Target on Alnylam Pharmaceuticals ..
MT
01/11ALNYLAM PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, F..
AQ
01/10ALNYLAM PHARMACEUTICALS : Launches “ P5x25” Strategy for Planned Tra..
BU
01/07ALNYLAM PHARMACEUTICALS : Says Late-Stage Study of Vutrisiran Meets Primary Endp..
MT
01/07ALNYLAM PHARMACEUTICALS : Reports Positive Topline Results from HELIOS-A Phase 3..
BU
01/04ALNYLAM PHARMACEUTICALS : to Webcast Presentation at 39th Annual J.P. Morgan Hea..
BU
2020ALNYLAM PHARMACEUTICALS : UBS Adjusts Price Target on Alnylam Pharmaceuticals to..
MT
2020ALNYLAM PHARMACEUTICALS : Appoints Tolga Tanguler Chief Commercial Officer and A..
BU
More news
Financials (USD)
Sales 2020 476 M - -
Net income 2020 -829 M - -
Net cash 2020 1 061 M - -
P/E ratio 2020 -24,0x
Yield 2020 -
Capitalization 19 753 M 19 753 M -
EV / Sales 2020 39,3x
EV / Sales 2021 23,7x
Nbr of Employees 1 323
Free-Float 99,2%
Chart ALNYLAM PHARMACEUTICALS, INC.
Duration : Period :
Alnylam Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 165,33 $
Last Close Price 170,02 $
Spread / Highest target 32,3%
Spread / Average Target -2,76%
Spread / Lowest Target -47,1%
EPS Revisions
Managers and Directors
NameTitle
John M. Maraganore Chief Executive Officer & Director
Yvonne L. Greenstreet President & Chief Operating Officer
Michael W. Bonney Chairman
Jeffrey Poulton Chief Financial & Accounting Officer
Akshay K. Vaishnaw President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ALNYLAM PHARMACEUTICALS, INC.30.81%19 753
MODERNA, INC.45.35%60 120
LONZA GROUP AG5.49%50 227
CELLTRION, INC.-10.58%39 891
IQVIA HOLDINGS INC.0.65%34 576
SEAGEN INC.-1.43%31 230